{"nctId":"NCT02558296","briefTitle":"Bexagliflozin Efficacy and Safety Trial","startDateStruct":{"date":"2015-10","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":1700,"armGroups":[{"label":"Bexagliflozin tablets, 20 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bexagliflozin"]},{"label":"Placebo tablets","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Bexagliflozin","otherNames":["EGT0001442","EGT0001474"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with a diagnosis of T2DM\n* Subjects who have had a stable treatment regimen for T2DM for the past 3 months\n* Subjects who present with at least one of the following 3 histories:\n\nGroup 1: A history of atherosclerotic vascular disease Group 2: A history of heart failure Group 3: Age ≥ 55 years with diabetes for ≥ 10 years, uncontrolled hypertension, currently smoking, reduced kidney function, or cholesterol problems\n\nExclusion Criteria:\n\n* Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young\n* History of genitourinary tract infections\n* Evidence of abnormal liver function\n* History of MI, stroke or hospitalization for heart failure in the past 3 months\n* Prior kidney transplant or evidence of kidney problems\n* Prior or planned pace maker implantation\n* Pregnant or nursing","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 24","description":"The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with increased risk of cardiovascular adverse events.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.85","spread":null},{"groupId":"OG001","value":"-0.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c at Week 24 for Subjects Who Have Been Prescribed Insulin","description":"To evaluate the effect of 20 mg bexagliflozin on the change in HbA1c from baseline to week 24 in randomized subjects who have been prescribed insulin to control their diabetes","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":null},{"groupId":"OG001","value":"-0.32","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to Week 48","description":"To evaluate the effect of 20 mg bexagliflozin on the change in body weight from baseline to week 48 in randomized subjects with a BMI ≥ 25 kg/m2 compared to placebo","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.03","spread":null},{"groupId":"OG001","value":"-0.38","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure From Baseline to Week 24 in Subjects Hypertensive at Baseline","description":"To evaluate the effect of 20 mg bexagliflozin on the change in systolic blood pressure (SBP) from baseline to week 24 in subjects with baseline systolic blood pressure ≥ 140 mmHg compared to placebo","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.83","spread":null},{"groupId":"OG001","value":"-6.87","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in HbA1c From Baseline Over Time","description":"To assess the effect of 20 mg bexagliflozin treatment on the change in HbA1c from baseline versus placebo over time up to 168 weeks","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":null},{"groupId":"OG001","value":"-0.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.89","spread":null},{"groupId":"OG001","value":"-0.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":null},{"groupId":"OG001","value":"-0.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.86","spread":null},{"groupId":"OG001","value":"-0.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":null},{"groupId":"OG001","value":"-0.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.76","spread":null},{"groupId":"OG001","value":"-0.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.68","spread":null},{"groupId":"OG001","value":"-0.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":null},{"groupId":"OG001","value":"-0.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.62","spread":null},{"groupId":"OG001","value":"-0.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.56","spread":null},{"groupId":"OG001","value":"-0.29","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Fasting Plasma Glucose Over Time","description":"To evaluate the effect of bexagliflozin treatment on the change in fasting plasma glucose (FPG) versus placebo over time up to 168 weeks","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":null},{"groupId":"OG001","value":"0.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.33","spread":null},{"groupId":"OG001","value":"0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.43","spread":null},{"groupId":"OG001","value":"-0.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.21","spread":null},{"groupId":"OG001","value":"-0.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":null},{"groupId":"OG001","value":"-0.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.14","spread":null},{"groupId":"OG001","value":"-0.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.16","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.90","spread":null},{"groupId":"OG001","value":"0.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.03","spread":null},{"groupId":"OG001","value":"-0.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.06","spread":null},{"groupId":"OG001","value":"-0.55","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification","description":"To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"0.18","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Proportion of Subjects Requiring an Intensification of Hypoglycemic Agent and Time to First Intensification","description":"To measure the proportion of subjects requiring an intensification of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study period","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"0.18","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent","description":"To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during 24 week period","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null},{"groupId":"OG001","value":"0.05","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Proportion of Subjects Requiring a Relaxation of Hypoglycemic Agent","description":"To measure the proportion of subjects requiring a relaxation of hypoglycemic agent in the bexagliflozin arm versus placebo during the entire study","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null},{"groupId":"OG001","value":"0.05","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Proportion of Participants With Incidence of Hospitalization for Heart Failure","description":"To measure the incidence of hospitalization for heart failure among all subjects and among subjects who have a history of heart failure at baseline","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":null},{"groupId":"OG001","value":"0.02","spread":null},{"groupId":"OG002","value":"0.05","spread":null},{"groupId":"OG003","value":"0.09","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":373,"n":1132},"commonTop":["Hypoglycaemia","Urinary tract infection","Upper respiratory tract infection","Nasopharyngitis","Hyperglycaemia"]}}}